Long‐term testosterone undecanoate treatment in the elderly testosterone deficient male: An observational cohort study
Abstract
Background: Quarterly intramuscular injections with long‐acting testosterone undecanoate (TU) provide stable serum testosterone concentrations over time and are therefore preferred by many testosterone‐deficient patients. However, the use of long‐acting TU in elderly patients is limited due to lack of safety and feasibility studies.Objective: To investigate long‐acting TU pharmacokinetics and assess differences in treatment regimens and risk of adverse outcomes in younger versus elderly testosterone‐deficient patients.Materials and methods: Single‐center longitudinal observational study. Patients who initiated long‐acting TU treatment between 2005 and 2010 were included. Elderly patients were born before 1956 and younger patients between 1965 and 1985. TU dose was adjusted yearly through shortening or prolongation of time between injections. Treatment targets were as follows: (1) free testosterone between 0 and −1 SD from the age‐adjusted mean, (2) no symptoms of testosterone deficiency, and (3) hematocrit within the normal range.Results: The study population consisted of 63 elderly and 63 younger patients. Median follow‐up time during testosterone replacement was 12.1 years. Increasing intervals between TU injections were performed 44% more often in the elderly compared to younger patients and time between TU injections were prolonged 4% more in the elderly patients. The hematocrit, as well as the hematocrit for a given serum testosterone (hematocrit: testosterone ratio), increased with treatment time but did not differ between age groups. During follow‐up, 40% of patients—both elderly and younger—experienced polycythemia. Risk of polycythemia did not differ with age.Discussion and conclusion: An increased number of adjustments of TU dose are necessary in elderly patients in order to reach treatment targets. TU treatment in elderly testosterone‐deficient patients is not associated with an increased risk of polycythemia compared to younger patients if age‐adjusted treatment targets are reached.Keywords
This publication has 26 references indexed in Scilit:
- Elevated Dihydrotestosterone is Associated with Testosterone Induced ErythrocytosisJournal of Urology, 2015
- Is anemia a new cardiovascular risk factor?International Journal of Cardiology, 2015
- UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecanoate. A Retrospective Experience from 207 Men with HypogonadismFrontiers in Endocrinology, 2013
- Pharmacokinetics and Safety of Long‐Acting Testosterone Undecanoate Injections in Hypogonadal Men: An 84‐Week Phase III Clinical TrialJournal of Andrology, 2010
- Hematocrit and risk of venous thromboembolism in a general population. The Tromso studyHaematologica, 2009
- Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men*The Journal of Clinical Endocrinology & Metabolism, 1999
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled TrialThe Journal of Clinical Endocrinology & Metabolism, 1997
- Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthateEuropean Journal of Endocrinology, 1995
- Smokers' PolycythemiaNew England Journal of Medicine, 1978